The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
